Anti-Poldip3

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

Biochem/physiol Actions

Polymerase δ-interacting protein 3 (POLDIP3) is deposited at the exon-junction complex and recruits S6K1 (ribosomal protein S6 kinase β-1) to the mRNA. POLDIP3 and S6K1 together are important to increase the translation efficiency of spliced mRNA. S6K1 lies downstream of mTOR (mammalian target of rapamycin) and PI3K (phosphoinositides 3-kinase), which are involved in cell growth promotion and cell cycle progression. Absence of S6K1 or S6K1 interacting partner POLDIP3 decreases cell size. IFN-α (interferon-α) induces phosphorylation of POLDIP3, thereby enhancing latter interaction with the eukaryotic initiation factor 4G. This pathway is important for regulation of mRNA translation of IFN-sensitive genes and induction of IFN-α biological response. POLDIP3 also interacts with the p50 subunit of DNA polymerase δ and enhancer of rudimentary protein.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Features and Benefits

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.Every Prestige Antibody is tested in the following ways: IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues. Protein array of 364 human recombinant protein fragments.

General description

The gene POLDIP3 (polymerase δ-interacting protein 3) is mapped to human chromosome 22q13.2. It is also popularly referred as SKAR. POLDIP3 is expressed ubiquitously, with highest levels in brain, heart, skeletal muscle, and kidney. The protein is mainly localized in the nucleus and exhibit a punctuate pattern. However, POLDIP3 can shuttle between the nucleus and the cytoplasm.

Immunogen

Polymerase delta-interacting protein 3 recombinant protein epitope signature tag (PrEST)

Legal Information

Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC

Linkage

Corresponding Antigen APREST74560.

Physical form

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide